Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →

Ensysce acquires Cy Biopharma for $77 million

PUBLIC · ENSCAug 07, 2026•8 days ago

Acquiring Company

Ensysce Biosciences

Acquired Company

Cy Biopharma

New YorkManufacturingHardwareFinancial ServicesFinanceFintechLendingBankingBiotechnologyHealth CarePharmaceuticalBiopharma

Description

Ensysce Biosciences has acquired Cy Biopharma for USD 77 million to enhance its pain therapeutics portfolio. With this acquisition, Ensysce shifts from an opioid focus to include neuroplastogenic therapies for complex regional pain syndrome. Former Cy shareholders will hold approximately 75% of the combined entity, effectively integrating Cy's pipeline into Ensysce.

Company Information

Company

Ensysce Biosciences

Location

Support@Grasshopperbank

New York, United States

About

Ensysce Biosciences, based in San Diego, CA is a clinical-stage biotech company using its two novel proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin-Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPARTM) platforms, the Company is seeking to develop next-generation, tamper-proof opioids that prevent both drug abuse and overdoses. Ensysce's products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing the human and economic costs. The platforms are covered by an extensive worldwide intellectual property portfolio encompassing a wide array of prescription drugs. For more information, please visit www.ensysce.com.

Don't miss Ensysce Biosciences's next move

Get an email the moment Ensysce Biosciences makes an acquisition, hires an exec, or expands — usually minutes after it happens.

One email per event. Unsubscribe anytime.

Related People

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for Ensysce Biosciences's next move

Learn about Strategic plan

M&A Insights

Based on deal data

Integration timeline

70% of M&A integrations take 12-24 months to complete

Tech stack consolidation

83% of merged companies consolidate technology vendors within first year

Post-acquisition investment

Companies increase IT spending by 23% on average after acquisitions

Success factor

M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired Cy Biopharma?

Cy Biopharma was acquired by Ensysce Biosciences, based in New York. The deal was reported on August 7, 2026. Ensysce Biosciences, based in San Diego, CA is a clinical-stage biotech company using its two novel proprietary technology platforms to develop safer prescription drugs. Ensysce Biosciences is publicly traded (ENSC) and operates in Manufacturing.

When did Ensysce Biosciences acquire Cy Biopharma?

Ensysce Biosciences's acquisition of Cy Biopharma was reported on August 7, 2026. Ensysce Biosciences has acquired Cy Biopharma for USD 77 million to enhance its pain therapeutics portfolio. With this acquisition, Ensysce shifts from an opioid focus to include neuroplastogenic therapies for complex regional pain syndrome. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Cy Biopharma do?

Cy Biopharma is a biopharmaceutical firm developing therapies for pain conditions. They focus on neuroplastogenic approaches to treat chronic pain syndromes. Their lead asset is a neuroplastogenic receptor agonist for complex regional pain syndrome. It is privately held, operating in Biotechnology.